Guggenheim Capital LLC Buys Shares of 67,358 Haleon plc (NYSE:HLN)

Guggenheim Capital LLC purchased a new stake in shares of Haleon plc (NYSE:HLN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 67,358 shares of the company's stock, valued at approximately $643,000.

Other large investors also recently modified their holdings of the company. Procyon Advisors LLC raised its holdings in shares of Haleon by 41.3% during the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock valued at $2,196,000 after buying an additional 67,329 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Haleon by 29.8% during the 4th quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after buying an additional 475,934 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock valued at $53,791,000 after buying an additional 1,026,939 shares in the last quarter. SeaCrest Wealth Management LLC purchased a new position in shares of Haleon during the 4th quarter valued at about $102,000. Finally, Douglas Lane & Associates LLC raised its holdings in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company's stock valued at $82,274,000 after buying an additional 161,865 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HLN. HSBC reissued a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Haleon presently has an average rating of "Hold" and an average target price of $10.95.

Haleon Trading Down 1.4 %

Shares of NYSE:HLN traded down $0.14 on Wednesday, hitting $10.14. The company had a trading volume of 17,713,012 shares, compared to its average volume of 7,474,673. The firm's 50-day simple moving average is $10.15 and its two-hundred day simple moving average is $9.81. The firm has a market capitalization of $45.75 billion, a price-to-earnings ratio of 29.82, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 1 year low of $8.12 and a 1 year high of $10.80.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Equities analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a $0.1166 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.